A Phase 1/2 Study of the Highly Selective EGFR Inhibitor BLU-701 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Egfr-mutant Non-small Cell Lung Cancer
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Pathologically confirmed metastatic Non-Small Cell Lung Cancer with EGFR mutation (exon 19 deletion or L858R) that has had previous treatment with an EGFR tyrosine kinase inhibitor.
- Able to swallow an oral medication.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
You may not be eligible for this study if the following are true:
-
- Have disease that is suitable for local therapy administered with curative intent.
- Have tumor that harbors EGFR T790M mutation or any additional known driver alterations.
- Have central nervous system metastases or spinal cord compression that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease.
- Have clinically active ongoing interstitial lung disease (ILD) of any etiology, including drug-induced ILD, and radiation pneumonitis within 28 days prior to initiation of study treatment.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.